1. Home
  2. HURA vs AXR Comparison

HURA vs AXR Comparison

Compare HURA & AXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • AXR
  • Stock Information
  • Founded
  • HURA 2009
  • AXR 1961
  • Country
  • HURA United States
  • AXR United States
  • Employees
  • HURA N/A
  • AXR N/A
  • Industry
  • HURA
  • AXR Homebuilding
  • Sector
  • HURA
  • AXR Real Estate
  • Exchange
  • HURA Nasdaq
  • AXR Nasdaq
  • Market Cap
  • HURA 246.9M
  • AXR 203.2M
  • IPO Year
  • HURA N/A
  • AXR N/A
  • Fundamental
  • Price
  • HURA $4.39
  • AXR $31.70
  • Analyst Decision
  • HURA
  • AXR
  • Analyst Count
  • HURA 0
  • AXR 0
  • Target Price
  • HURA N/A
  • AXR N/A
  • AVG Volume (30 Days)
  • HURA 668.3K
  • AXR 34.9K
  • Earning Date
  • HURA 02-15-2025
  • AXR 12-31-2024
  • Dividend Yield
  • HURA N/A
  • AXR N/A
  • EPS Growth
  • HURA N/A
  • AXR N/A
  • EPS
  • HURA N/A
  • AXR 2.30
  • Revenue
  • HURA N/A
  • AXR $63,223,000.00
  • Revenue This Year
  • HURA N/A
  • AXR N/A
  • Revenue Next Year
  • HURA N/A
  • AXR N/A
  • P/E Ratio
  • HURA N/A
  • AXR $13.88
  • Revenue Growth
  • HURA N/A
  • AXR 54.34
  • 52 Week Low
  • HURA $2.84
  • AXR $15.88
  • 52 Week High
  • HURA $14.60
  • AXR $39.67
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • AXR 38.66
  • Support Level
  • HURA N/A
  • AXR $30.29
  • Resistance Level
  • HURA N/A
  • AXR $33.50
  • Average True Range (ATR)
  • HURA 0.00
  • AXR 1.97
  • MACD
  • HURA 0.00
  • AXR -0.91
  • Stochastic Oscillator
  • HURA 0.00
  • AXR 7.57

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About AXR AMREP Corporation

Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.

Share on Social Networks: